ClinicalTrials.gg
Not yet recruitingNCT07755371Updated Aug 10, 2026

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps

A Phase 2 interventional study of AK139 and Placebo in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Planned enrollment
25th of 43
75 · median 90
Started
2026
with 9 others
Phase 2
13 of 46
4 open now
Primary completion
2027-04
later than 14 of 23 live
Registered
45th of 46
by date
Lead sponsor
1 of 46
Akeso

Among the 46 studies in Nasal Polyps with a site in China, this one is the 25th largest by planned enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 14 of the 23 other live ones, and was the 45th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 injection compared with placebo in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) receiving background treatment with mometasone furoate nasal spray (MFNS).

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).

Eligible participants will be randomized to receive AK139 or placebo in addition to background treatment with mometasone furoate nasal spray (MFNS). The study will assess the effect of AK139 on nasal polyp burden, disease symptoms, health-related quality of life, safety, PK, PD, and immunogenicity throughout the study period.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 75 years (inclusive) at the time of signing the form (ICF).
  2. Bilateral CRSwNP with prior treatment with systemic (SCS), to or intolerance of SCS, and/or prior nasal polyp surgery.
  3. Nasal Polyp Score (NPS) ≥5, with a minimum score of 2 in each nasal cavity, at screening and baseline.
  4. Ongoing nasal congestion/obstruction, with a Nasal Congestion Score (NCS) of 2 or 3 at screening and baseline.
  5. Use of intranasal corticosteroids for at least 4 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. History of sinonasal surgery (including nasal polypectomy) within 6 months prior to screening, or prior nasal surgery resulting in structural changes that preclude adequate assessment of Nasal Polyp Score (NPS).
  2. Presence of any of the following conditions:

    • Antrochoanal polyp;
    • Persistent rhinitis medicamentosa;
    • Allergic fungal rhinosinusitis with symptoms and/or CT findings.
  3. Nasal malignant or benign tumors.
  4. Severe nasal septal deviation causing obstruction of at least one nostril.
  5. Known eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, cystic fibrosis, primary ciliary dyskinesia, or other systemic diseases associated with nasal polyposis.
  6. Participants with asthma and ≤50% of the predicted value at screening or baseline.
  7. Parasitic infection, active tuberculosis, recurrent or chronic infectious diseases, or diseases.
  8. Acute sinusitis, nasal infection, or upper respiratory tract infection within 2 weeks prior to screening or during the screening period.
  9. Chronic infection with virus, virus, (HIV), or syphilis.
  10. Treatment with anti-IL-4Rα monoclonal antibodies, anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, anti-immunoglobulin E (IgE) monoclonal antibodies, or other biologic agents within 10 weeks or 5 half-lives (whichever is longer) before randomization, or prior treatment with AK139.
  11. Treatment with short- or intermediate-acting systemic within 4 weeks prior to screening, or long-acting systemic corticosteroids within 6 weeks prior to screening.
  12. Prior treatment with anti-IL-4Rα monoclonal antibodies with inadequate clinical response.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    AK139 regimen 1

    AK139 regimen 1 will be administered by subcutaneous injection

    Biological: AK139

  • Experimental
    AK139 regime 2

    AK139 regime 2 will be administered by subcutaneous injection.

    Biological: AK139

  • Placebo comparator
    Placebo

    Placebo will be administered by subcutaneous injection.

    Biological: Placebo

Interventions

  • BiologicalAK139

    AK139 administered subcutaneously

  • BiologicalPlacebo

    Placebo administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Nasal Polyp Score (NPS)

    Change from baseline in Nasal Polyp Score (NPS). NPS is a bilateral endoscopic assessment scale for nasal polyposis, where each nasal cavity is scored from 0 to 4. The total score is the sum of the left and right sides, ranging from 0 to 8, with higher scores indicating more severe nasal polyp disease.

    Time frame: Baseline and Week 16

  2. Nasal Congestion Score (NCS)

    Change from baseline in Nasal Congestion Score (NCS). NCS is a patient-reported outcome measure using a 4-point Verbal Rating Scale (VRS) ranging from 0 to 3. Higher scores indicate more severe nasal congestion.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Nasal Polyp Score (NPS)

    Change from baseline in Nasal Polyp Score (NPS) at each assessment visit.

    Time frame: From baseline to Week 20 (excluding Week 16)

  2. Nasal Congestion Score (NCS)

    Change from baseline in Nasal Congestion Score (NCS) at each assessment visit.

    Time frame: From baseline through Week 20 (excluding Week 16)

  3. Total Symptom Score (TSS)

    Change from baseline in Total Symptom Score (TSS) at each assessment visit. TSS ranged from 0 to 9, with higher scores indicating greater nasal symptom severity.

    Time frame: From baseline to Week 20

  4. Sino-Nasal Outcome Test-22 (SNOT-22)

    Change from baseline in Total Score of Sino-Nasal Outcome Test-22 (SNOT-22) at each assessment visit. SNOT-22 is a validated patient-reported questionnaire used to assess symptom severity and health-related quality of life (HRQoL) in patients with chronic rhinosinusitis (CRS). Scores range from 0 to 110, with higher scores indicating greater symptom burden and poorer HRQoL.

    Time frame: From baseline to Week 20

  5. Lund-Mackay Score

    Change from baseline in Lund-Mackay Score on CT scan. The Lund-Mackay score ranges from 0 to 24, with higher scores indicating more severe sinonasal disease.

    Time frame: Baseline and Week 16

  6. Safety parameters

    Assessment of safety, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and clinically significant findings from physical examinations, laboratory tests, vital signs, and 12-lead electrocardiograms (ECGs).

    Time frame: Up to Week 20

  7. Pharmacokinetics (PK)

    Serum concentrations of AK139 following administration.

    Time frame: Up to Week 20

  8. Pharmacodynamics (PD)

    Change from baseline in serum biomarker levels.

    Time frame: From baseline to Week 20

  9. Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb)

    Incidence of Anti-drug antibodies(ADA) and Neutralizing antibody (Nab) after treatment.

    Time frame: Up to Week 20

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartEst.
Aug 10, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07755371
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Aug 10, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 399

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK139

Start the discussion